Buscar
Mostrando ítems 1-10 de 14
Mechanisms of Cellular Uptake, Intracellular Transportation, and Degradation of CIGB-300, a Tat-Conjugated Peptide, in Tumor Cell Lines
(American Chemical Society, 2014-04)
CIGB-300 is a cyclic synthetic peptide that induces apoptosis in malignant cells, elicits antitumor activity in cancer animal models, and shows tumor reduction signs when assayed in first-in-human phase I trial in patients ...
Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastasic colonization
(Nature, 2020-09-07)
CK2 is a serine/threonine kinase that is overexpressed in breast cancer and its inhibition is associated to reduced tumor growth and disease progression. CIGB-300 is an antitumor peptide with a novel mechanism of action, ...
Synergistic interactions of the anti‑casein kinase 2 CIGB‑300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models
(Spandidos Publications, 2014-07)
CIGB‑300 is a novel clinical‑stage synthetic peptide that impairs the casein kinase 2 (CK2)‑mediated phosphorylation of B23/nucleophosmin in different experimental settings and cancer models. As a single agent, CIGB‑300 ...
CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models
(Elsevier Ireland, 2017-05)
Objectives: Casein kinase 2 (CK2) is overexpressed in several types of cancer. It has more than 300 substrates mainly involved in DNA reparation and replication, chromatin remodeling and cellular growth. In recent years ...
Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer
(Nature Publishing Group, 2015-05)
Background:We conducted a phase 1 trial in patients with locally advanced cervical cancer by injecting 0.5 ml of the CK2-antagonist CIGB-300 in two different sites on tumours to assess tumour uptake, safety, pharmacodynamic ...
The synthetic peptide CIGB-300 modulates CK2-dependent signaling pathways affecting the survival and chemoresistance of non-small cell lung cancer cell lines
(BioMed Central, 2017-03)
Background: Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer-related deaths worldwide. Up to 80% of cancer patients are classified as non-small-cell lung cancer (NSCLC) and cisplatin ...
CIGB-300 anticancer peptide regulates the protein kinase CK2-dependent phosphoproteome
(Springer, 2020-05-13)
Casein-kinase CK2 is a Ser/Thr protein kinase that fosters cell survival and proliferation of malignant cells. The CK2 holoenzyme, formed by the association of two catalytic alpha/alpha’ (CK2α/CK2α’) and two regulatory ...
Efecto del péptido sintético CIGB-300 en vías de señalización dependientes de CK2 : implicancia en el tratamiento del cáncer de pulmón de células no pequeñas en un modelo preclínico
(Universidad Nacional de Quilmes, 2017-05-26)
El cáncer de pulmón es la principal causa de muerte por cáncer en nuestro país y en el mundo. Más del 80% de los casos corresponden al subtipo de cáncer de pulmón de células no pequeñas (NSCLC). El cisplatino ...
Pharmacologic inhibition of the CK2-mediated phosphorylation of B23/NPM in cancer cells selectively modulates genes related to protein synthesis, energetic metabolism, and ribosomal biogenesis
(Springer, 2015-06)
B23/NPM is a multifunctional nucleolar protein frequently overexpressed, mutated, or rearranged in neoplastic tissues. B23/NPM is involved in diverse biological processes and is mainly regulated by heteroligomer association ...